Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | CNR1 | P21554 | 7/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973728 | 1.00 | CNR2 (0.36) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL19973787 | 1.00 | CNR2 (0.36) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL19973786 | 1.00 | CNR2 (0.36) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL355026 | 0.97 | — | — | |
| SCHEMBL355025 | 0.97 | — | — | |
| SCHEMBL19973858 | 0.84 | SOAT1 (0.38) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL19973856 | 0.84 | SOAT1 (0.38) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL28730927 | 0.84 | SOAT1 (0.38) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL19973821 | 0.82 | SOAT1 (0.41) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL19973820 | 0.82 | SOAT1 (0.41) | CNR2CNR1TRPA1TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715605-B | Process for preparing carotenoid monoesters | 巴斯夫欧洲公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2018050792-A1 | PROCESS FOR PREPARING ESTERS OF 12'-APOCAROTENALS AS BUILDING BLOCKS FOR CAROTENOIDS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050793-A1 | PROCESS FOR PREPARING PHOSPHONIUM SALT ESTERS AS BUILDING BLOCKS FOR CAROTENOIDES | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050795-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050794-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CNR2 327/4885CNR1 197/4885TRPA1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.